Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 3

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 3
---
 all of the information you should consider before investing in our securities. Before making an investment decision, to fully understand this offering and its consequences to you, you should carefully read this entire prospectus supplement and the accompanying prospectus, including “Risk Factors” beginning on page S-6 of this prospectus supplement and the financial statements and related notes and the other information that we incorporate by reference into this prospectus supplement.

Our Business

We are a clinical-stage biopharmaceutical company developing first-in-class, off-the-shelf invariant natural killer T (iNKT) cell therapies designed to treat
cancer and immune-mediated diseases. Our therapies are based on a proprietary platform of allogeneic, ex-vivo expanded iNKT cells—cells that are designed to uniquely combine the precision and memory of adaptive T cells with the speed and
potency of natural killer (NK) cells. This rare biology is designed to allow iNKT cells to navigate tissues, eliminate tumors and infected cells, and reprogram the immune environment—all without graft-versus-host disease (GVHD).

We believe iNKT cells represent an optimal platform for off-the-shelf cellular immunotherapy. Unlike conventional T or NK cell therapies, our iNKT cells can
persist without lymphodepletion and function without the need for human leukocyte antigen (HLA) matching. This allows for scalable, repeatable, and widely accessible treatment options in indications with significant unmet need.

Our approach includes the development of both native and engineered iNKT cell therapies. Our pipeline includes wholly owned and exclusively licensed assets
targeting solid tumors, pulmonary immune failure, and immune-related disorders. We have also developed a proprietary neoantigen library that supports personalized TCR development by identifying patient-specific tumor signatures. These insights can
be used to create highly tailored TCR-iNKT therapies, enabling precision targeting across cancers and complex immune pathologies.

Our lead product
candidate, agenT-797, is an allogeneic, native iNKT cell therapy in development for both oncology and immune-mediated diseases. In a clinical trial (NCT05108623) involving patients with treatment-refractory solid tumors, agenT-797 was evaluated as
monotherapy and in combination with PD-1 inhibitors nivolumab or pembrolizumab. Treatment was associated with reductions in target and non-target lesions and durable disease stabilization, including a partial response in a patient with
checkpoint-refractory gastric cancer. AgenT-797 also demonstrated long